Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Schottenfeld, Richard S.; Mazlan, Mahmud

doi:10.1016/s0140-6736(08)60954-x

Cited by 89 publications

(79 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expansion of services has resulted in an estimated 7,000 individuals currently receiving treatment [14]. Research studies of MAT in Malaysia have compared naltrexone treatment to buprenorphine maintenance treatment in a randomized controlled trial and found that buprenorphine was superior in treatment retention to oral naltrexone [126].…”

Section: Australiamentioning

confidence: 99%

International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence

Kresina¹

2012

Clinic Experiment Pharmacol

View full text Add to dashboard Cite

Until recently, the global availability and consumption of opioid agonists and psychotropic medications have been below the levels needed for research to demonstrate local efficacy and to develop local evidence-based best medical practices. In addition, the global availability and use of opioid agonists and psychotropic medications have not been sufficient to implement the well documented efficacy shown for the treatment of opioid dependence that has been developed by research over the last 40 years. This strong research base has resulted in the development of evidencebased medical practices, such as Medication Assisted Treatment (MAT) for opioid dependence. The recognition of MAT as an effective medical treatment for opioid abuse and dependence has resulted in a substantial global increase in the medical use of opioid agonists and psychotropic medications to address opioid dependence. This increase is particularly evident in the initiation of new MAT programs in regions of Europe, North America, Africa, Asia and Oceania. While in other regions of the world, the medical use of opioid agonists and psychotropic medications have not substantially increased, the implementation of MAT programs have begun as part of the global effort to reduce HIV/AIDS. These HIV prevention programs have utilized MAT as an element of programs that target injection drug users to reduce their risk of both acquiring and transmitting HIV infection. Thus, this article documents the recent international expansion of the use of MAT for opioid dependence as a result of efforts to increase access and availability of evidence based treatments for opioid dependence as well as efforts to reduce the spread of infectious diseases, such as HIV/AIDS.

show abstract

Section: Australiamentioning

confidence: 99%

International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence

Kresina¹

2012

Clinic Experiment Pharmacol

View full text Add to dashboard Cite

show abstract

“…A full review of these therapies is beyond the scope of this article; however, several relevant reviews exist (Magura et al, 2007;Schottenfeld, Chawarski, & Mazlan, 2008). Agonist MAT involves pharmacological substitution of the opioid of abuse with controlled dosing of a long-acting opioid, which reduces cravings and the likelihood of relapse (Bell, Burrell, Indig, & Gilmour, 2006).…”

Section: Treatment Options For Od Patientsmentioning

confidence: 99%

“…The relationship between treatment outcomes and adherence with medication has been documented within many diseases, including addiction (Cramer et al, 2003;Schottenfeld et al, 2008). Results largely indicate that patients with chronic diseases who are adherent with their medication regimen tend to have better outcomes (Dolor et al, 2009).…”

Section: Treatment Options For Od Patientsmentioning

confidence: 99%

A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: Study feasibility and sample description

Ruetsch¹,

Cacciola

Tkacz³

2010

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

“…Buprenorphine is effective in treating opioid use disorder (Ling et al, 1998, Fudala et al, 2003, Fiellin et al, 2006, Schottenfeld et al, 2008) and is considered an essential medication for this indication (World Health Organization, 2013). Since receiving Food and Drug Administration approval in 2002, buprenorphine has significantly increased treatment capacity for opioid use disorder in the U.S. (Arfken et al, 2010, Greene, 2010).…”

Section: Introductionmentioning

confidence: 99%

The Availability of Ancillary Counseling in the Practices of Physicians Prescribing Buprenorphine

Barry

Fazzino

Necrason

et al. 2016

Journal of Addiction Medicine

View full text Add to dashboard Cite

Objectives We set out to examine physicians’ perceptions of the provision of ancillary services for opioid dependent patients receiving buprenorphine. Methods An email invitation describing the study was sent out by the American Society of Addiction Medicine to its membership (approximately 3,700 physicians) and other entities (for a total of approximately 7,000 email addresses). Email recipients were invited to participate in a research study funded by the National Institutes on Drug Abuse involving completion of an online survey; 346 physicians completed the survey. Results The majority of the 346 respondents were internal or family medicine (37%) or addiction medicine providers (30%) who were practicing in urban (57%) or suburban settings (27%). Most respondents reported either offering (66%) or referring patients for ancillary counseling (31%). Interventions that were most frequently offered or referrals provided were individual counseling (51%) and self-help groups (63%), respectively. Counseling availability differed significantly by provider specialization for any, individual, group, family or couples, and self-help groups. Conclusions Generally, respondents reported compliance with ancillary counseling requirements for buprenorphine treatment of opioid use disorder. In addition to examining the efficacy of a variety of ancillary counseling services for patients receiving opioid agonist treatment, further research should examine physicians’ attitudes toward the role of such counseling in buprenorphine treatment. While the study sample was relatively large, the generalizability of the findings is unclear, suggesting that further investigation of the availability of ancillary counseling in buprenorphine treatment among a larger nationally representative sample of providers may be warranted.

show abstract

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Cited by 89 publications

References 34 publications

International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence

International Expansion of the Use of Pharmacotherapies for the Treatment of Opioid Dependence

A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: Study feasibility and sample description

The Availability of Ancillary Counseling in the Practices of Physicians Prescribing Buprenorphine

Contact Info

Product

Resources

About